The studies are conducted in well-established ferret models with high predictability for future responses in humans and are intended to generate a broad and robust data package ahead of the next development step, the company states.

During 2025, Abera presented promising results from several preclinical studies of its influenza vaccine candidate. Among other findings, the studies demonstrated 100% survival in the vaccinated group following exposure to influenza virus, compared to 80% mortality in the unvaccinated group; no detectable virus in either the nasal mucosa or the lungs; and high antibody levels both systemically and in the mucosa. Additional studies showed strong and long-lasting immune responses; that both powder formulation and nasal spray administration produced comparable results; and that the vaccine exhibits good stability during long-term storage.

CEPI approves an extension of the ongoing project

As a result, the Coalition for Epidemic Preparedness Innovations (CEPI) has approved an extension of the ongoing project until 30 June in order to enable additional and broader preclinical studies during the spring. Through a reprioritization within the project, budget has been released for further preclinical work, while the project’s total budget remains unchanged.

“By reallocating resources within the project, we are able to conduct larger and more extensive studies to further deepen and broaden the data package at a stage where quality and predictability are critical. This allows us to advance further in the project, and with promising results from these studies we see good opportunities to take the next step in development,” says Maria Alriksson, CEO of Abera Bioscience.

The CEPI project has been extended until 30 June 2026 with the total budget remaining unchanged. The company assesses that the planned studies during the spring are covered by the grant received from CEPI and that the project therefore has full financial coverage for the upcoming development phase.